These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9791062)

  • 1. Peripheral corticotropin-releasing factor mediates the elevation of plasma IL-6 by immobilization stress in rats.
    Ando T; Rivier J; Yanaihara H; Arimura A
    Am J Physiol; 1998 Nov; 275(5):R1461-7. PubMed ID: 9791062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel high-affinity photoactivatable antagonists of corticotropin-releasing factor (CRF) photoaffinity labeling studies on CRF receptor, type 1 (CRFR1).
    Bonk I; Rühmann A
    Eur J Biochem; 2000 May; 267(10):3017-24. PubMed ID: 10806401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats.
    Rodríguez de Fonseca F; Rubio P; Menzaghi F; Merlo-Pich E; Rivier J; Koob GF; Navarro M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):56-64. PubMed ID: 8558457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat.
    Rivier J; Gulyas J; Corrigan A; Martinez V; Craig AG; Taché Y; Vale W; Rivier C
    J Med Chem; 1998 Dec; 41(25):5012-9. PubMed ID: 9836619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats.
    Menzaghi F; Howard RL; Heinrichs SC; Vale W; Rivier J; Koob GF
    J Pharmacol Exp Ther; 1994 May; 269(2):564-72. PubMed ID: 8182523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function.
    Martínez V; Rivier J; Wang L; Taché Y
    J Pharmacol Exp Ther; 1997 Feb; 280(2):754-60. PubMed ID: 9023288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of peptide CRF receptor antagonists upon the behavioural effects of human/rat CRF.
    Jones DN; Kortekaas R; Hatcher PD; Middlemiss DN; White A; Hagan JJ
    Eur J Pharmacol; 1999 Jun; 373(2-3):141-5. PubMed ID: 10414432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor.
    Gulyas J; Rivier C; Perrin M; Koerber SC; Sutton S; Corrigan A; Lahrichi SL; Craig AG; Vale W; Rivier J
    Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10575-9. PubMed ID: 7479843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks peripheral CRF- and abdominal surgery-induced delayed gastric emptying in rats.
    Martínez V; Rivier J; Taché Y
    J Pharmacol Exp Ther; 1999 Aug; 290(2):629-34. PubMed ID: 10411571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human urocortin II, a new CRF-related peptide, displays selective CRF(2)-mediated action on gastric transit in rats.
    Million M; Maillot C; Saunders P; Rivier J; Vale W; Taché Y
    Am J Physiol Gastrointest Liver Physiol; 2002 Jan; 282(1):G34-40. PubMed ID: 11751155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges.
    Koerber SC; Gulyas J; Lahrichi SL; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
    J Med Chem; 1998 Dec; 41(25):5002-11. PubMed ID: 9836618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins).
    Erchegyi J; Wang L; Gulyas J; Samant M; Perrin MH; Lewis K; Miller C; Vaughan J; Donaldson C; Fischer W; Low W; Yakabi S; Karasawa H; Taché Y; Rivier C; Rivier J
    J Med Chem; 2016 Feb; 59(3):854-66. PubMed ID: 26789203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral urocortin delays gastric emptying: role of CRF receptor 2.
    Nozu T; Martinez V; Rivier J; Taché Y
    Am J Physiol; 1999 Apr; 276(4):G867-74. PubMed ID: 10198329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice.
    Martínez V; Wang L; Rivier J; Grigoriadis D; Taché Y
    J Physiol; 2004 Apr; 556(Pt 1):221-34. PubMed ID: 14755002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of urocortin 2 secreted by the pituitary in the stress-induced suppression of luteinizing hormone secretion in rats.
    Nemoto T; Iwasaki-Sekino A; Yamauchi N; Shibasaki T
    Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E567-75. PubMed ID: 20663987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of corticotropin-releasing factor receptors type 1 and 2 in modulating the rat adrenocorticotropin response to stressors.
    Rivier CL; Grigoriadis DE; Rivier JE
    Endocrinology; 2003 Jun; 144(6):2396-403. PubMed ID: 12746300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 1 beta mediates stress-induced immunosuppression via corticotropin-releasing factor.
    Saperstein A; Brand H; Audhya T; Nabriski D; Hutchinson B; Rosenzweig S; Hollander CS
    Endocrinology; 1992 Jan; 130(1):152-8. PubMed ID: 1309324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats.
    Nozu T; Miyagishi S; Nozu R; Takakusaki K; Okumura T
    J Gastroenterol; 2017 Jan; 52(1):72-80. PubMed ID: 27075754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists.
    de Groote L; Peñalva RG; Flachskamm C; Reul JM; Linthorst AC
    J Neurochem; 2005 Jul; 94(1):45-56. PubMed ID: 15953348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser7 substitutions.
    Cervini L; Theobald P; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
    J Med Chem; 1999 Feb; 42(4):761-8. PubMed ID: 10052982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.